Pancreatic cancer is a deadly disease and has the worst prognosis among almost all cancers and is in dire need of new and improved therapeutic strategies. Conditioning of tumor cells with chemotherapeutic drug has been shown to enhance the anti-tumor effects of cancer vaccines and adoptive cell therapy. In this study, we investigated the immunomodulatory effects of pan-Bcl-2 inhibitor AT-101 on pancreatic cancer (PC) cell cytotoxicity by activated T cells (ATC). The effects of AT-101 on cytotoxicity, early apoptosis, and Granzyme B (GrzB) and IFN-c signaling pathways were evaluated during EGFR bispecific antibody armed ATC (aATC)-mediated killing of L3.6pl and MiaPaCa-2 PC cells pre-sensitized with AT-101. We found that pretreatment of tumor cells with AT-101 enhanced susceptibility of L3.6pl and MiaPaCa-2 tumor cells to ATC and aATC-mediated cytotoxicity, which was in part mediated via enhanced release of cytolytic granule GrzB from ATC and aATC. AT-101-sensitized L3.6pl cells showed up-regulation of IFN-c-mediated induction in the phosphorylation of Ser 727 -Stat1 (pS 727 -Stat1), and IFN-c induced dephosphorylation of phospho-Tyr 705 -Stat3 (pY 705 -Stat3). Priming (conditioning) of PC cells with AT-101 can significantly enhance the anti-tumor activity of EGFRBi armed ATC through increased IFN-c induced activation of pS 727 -Stat1 and inhibition of pY 705 -Stat3 phosphorylation, and resulting in increased ratio of pro-apoptotic to anti-apoptotic proteins. Our results verify enhanced cytotoxicity after a novel chemotherapy conditioning strategy against PC that warrants further in vivo and clinical investigations.
Introduction
Although chemotherapy is considered myelo-and immunosuppressive [1] , the combination of a number of chemotherapeutic regimens have been shown to enhance the anti-tumor effects of cancer vaccines and adoptive cell therapy [2] [3] [4] [5] [6] [7] . Pretreatment of tumors with chemotherapy has not only shown improved antitumor efficacy of immunotherapy, but has also shown success in breaking self-tolerance by eliminating MDSC and attenuating the tumor suppressive environment leading to enhanced anti-tumor immunity [8] [9] [10] [11] . On the other hand, tumor sensitization with immunotherapy prior to chemotherapy, the ''chemocentric chemoimmunotherapy'' approach has also shown profound enhancement of the cytotoxic effect of chemotherapeutic drugs [12] .
Among the emerging members of small molecule pan-Bcl-2 inhibitors, AT-101(R-(-)-gossypol acetic acid), a polyphenolic compound, has been shown to inhibit Bcl-2 by acting as a BH3 mimetic which disrupts the heterodimerization of Bcl-2, Mcl-1, and Bcl-X L with proapoptotic family members [13] [14] [15] [16] . As a single agent in multiple Phase I and Phase II trials, AT-101 exhibited cytoreductive activity in chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and prostate cancer patients [17] [18] [19] . While in other Phase I/II studies in solid tumors, AT-101 either as a single agent or in combination therapy failed to show clinical efficacy mainly due to dose related toxicities [20, 21] . We hypothesized that combining pan-Bcl-2 inhibitor AT-101 at a suboptimal concentration with targeted activated T-cells may offer a greater treatment efficacy.
Pancreatic cancer (PC) remains a deadly and by far incurable disease killing over 33,000 US citizens annually, and five year survival is less than 5% [22] . Standard chemotherapy involving gemcitabine has negligible impact on the dismal statistics while neo adjuvant therapies involving combination regimens such as FOLFURINOX have shown only marginal benefits [23] . Thus, novel therapies are urgently needed for the treatment of pancreatic cancer. Small molecule inhibitors that target the intracellular tyrosine kinase signaling pathways of EGFR, such as gefitinib (IressaH) or erlotinib (TarcevaH) have been tested in clinical trials without major impact on the disease in spite of the fact that EGFR is over-expressed in 30-50% of pancreatic cancer [24] [25] [26] . However, targeting EGFR through bispecific antibody (EGFRBi) armed activated T-cells (aATC) offers a novel and non-toxic approach that exploits EGFR over-expression independent of EGFR activation state and/or mutations. We compared the antitumor effects of combining a suboptimal concentration of AT-101 with EGFRBi armed ATC or the effect of each individually. Our data show that pre-sensitization of tumor cells with a suboptimal concentration of AT-101 can significantly enhance the anti-tumor activity of EGFRBi armed ATC, and thus this strategy could be useful for designing novel therapies for the treatment of PC.
Materials and Methods

Cell Lines and Reagents
The human pancreatic cancer (PC) cell lines (MiaPaCa-2, and CoLo-357) were obtained from American Type Culture Collection (Rockville, MD). The human pancreatic L3.6pl cells were established from Colo-357 cells by injecting them into the pancreas of nude mice [27] . These cell lines were maintained in RPMI-1640 or DMEM culture media (Lonza Inc., Allendale, NJ) supplemented with 10% FBS (Lonza Inc.), 2 mM L-glutamine (Invitrogen, Carlsbad, CA), 50 units/ml penicillin, and 50 mg/ml streptomycin (Invitrogen). Pan-Bcl-2 inhibitor, AT-101 was a gift from Shaomeng Wang (Ann Arbor Michigan). Antibodies for flow cytometry were purchased from BD Biosciences and Cell Signaling Technologies.
Expansion and Generation of ATC and Production of Anti-OKT36Anti-EGFR Bispecific Antibodies
Human PBMC were isolated from the heparinized whole blood of normal healthy donors using lymphocyte separation solution. The Wayne State University Institutional Review Board approved research protocols for blood collection from normal healthy donors. All normal donors signed consent forms. Activated T cells (ATC) from PBMC were expanded using 20 ng/ml of OKT3 and 100 IU/ml of IL-2 for 14 days at a concentration of 1-2610 6 PBMC/ml in RPMI-1640 supplemented with 10% FBS. Bispecific Antibodies (BiAb) were produced by chemical heteroconjugation of OKT3 (a murine IgG2 a anti-CD3 monoclonal antibody, Ortho Biotech, Horsham, PA) and Erbitux (a chimeric anti-EGFR IgG 1 , Bristol-Myers Squibb, Princeton, NJ) as described earlier [28] . ATC were armed with anti-CD36anti-EGFR (EGFRBi) bispecific antibodies (aATC) following a previously optimized concentration of BiAb [29] (50 ng/10 6 ATC) for 30 minutes prior to its use in experiments.
Cytotoxicity Assay
Cytotoxicity testing was performed using chromium release assay using 51 Cr labeled L3.6pl and MiaPaCa-2 cells as described earlier [30] . Briefly, tumor cells were seeded in 96-well plates at 40,000 cells/well in a volume of 100 ml. Cells were allowed to adhere overnight before 0.5 mM and 1 mM AT-101 (these concentrations were chosen based on our dose titration experiments documenting minimal cytotoxicity) was added and incubated for 24-72 h. Following priming, cells were washed to remove AT-101 before labeling with 51 Cr. EGFRBi armed ATC were added at 10:1 effector to target (E:T) ratio for additional overnight incubation with 51 Cr labeled targets. AT-101 alone, unarmed ATC or armed ATC alone served as controls at each time point. Experiments were repeated three times in quadruplicate wells to ensure the reproducibility.
Detection of Early Apoptosis
For detection of apoptosis, untreated and 1 mM AT-101 treated PC cells were incubated for 24 h followed by 1-4 h of incubation with EGFRBi armed ATC at 10:1 E:T. Cells were then stained with Annexin V-FITC (BD Biosciences) and the viability dye 7-AAD. The proportion of Annexin V-positive cells was measured within the population of tumor cells by flow cytometry. All cells prepared for flow cytometry were analyzed using FACSCalibur instrumentation (BD) and FlowJo software.
Flow Cytometric Quantification of Markers for Apoptotic Pathway
Untreated and 1 mM AT-101 treated L3.6pl and MiaPaCa-2 cells were incubated for 24 h, followed by 1-4 h of incubation with EGFRBi armed ATC at 10:1 E:T. AT-101 alone, unarmed ATC or armed ATC alone served as controls at each time point. For intracellular staining, brefeldin A, a protein transport inhibitor, was added during incubation of effectors with targets. At the end of incubation, ATC or aATC were removed by washing twice, adherent tumor cells were removed by trypsinization. The cells were washed, fixed, and permeabilized with Fix/ Perm solution (BD Biosciences) and then stained for 60 minutes on ice with fluorochrome-labeled anti-phospho-Stat1 (Phospho-Stat1, Ser727), anti-phospho-Stat3 (Phospho-Stat3, Tyr705), anti-Bcl-X L , anti-Bax, anti-phospho-Bad (Phospho-Bad,Ser112) rabbit monoclonal antibodies (Cell Signaling Technology) followed by flow cytometric analysis. For surface staining, the cells were blocked with 5% human serum in PBS for 30 minutes and labeled with mouse monoclonal anti-CD3-FITC or anti-EpCAM-APC antibodies (BD Biosciences) for 30 minutes followed by washing and fixing in 2% paraformaldehyde in PBS and analyzed by flow cytometry.
Staining for IFN-c, Granzyme B and Degranulation Markers
PC cells, L3.6pl and MiaPaCa-2, were treated with 1 mM of AT-101 for 24 h prior to the assay. The cells from both untreated and AT-101-treated groups were incubated for 1-4 h with EGFRBi armed ATC at 10:1 E:T. Target cells were stained for surface and intracellular granzyme (GrzB) and degranulation markers, CD107a and CD107b. In a separate experiment degranulation of ATC and aATC following stimulation was stopped by GolgiStop. ATC or aATC were then stained for intracellular GrzB and CD107a/b using Perm/Fix kit and corresponding antibodies from BD Biosciences. The percentage of GrzB and CD107a/b positive cells was calculated for tumor cells, ATC, and aATC in each group.
IFN-c ELISA of Culture Supernatants
Cytokines were quantitated in culture supernatants collected from untreated or AT-101 treated cultures in the presence or absence of ATC or aATC using ELISA kit as per manufacturer's instruction (R&D Systems).
Statistical Analysis
Quantitative data are presented as the mean of at least three or more independent experiments 6 standard deviation. A one-way ANOVA was used to determine whether there were statistically significant differences within each experiment. Differences between groups were tested via an unpaired, two-tailed t test.
Results
Enhanced Anti-Tumor Effect of Armed ATC (aATC) in AT-101 Primed Tumor Cells
We investigated whether the chemotherapy agent can affect the susceptibility of tumor cells to the lytic effect of aATC. We treated three PC cell lines with 0.1, 0.5, 1.0 and 5.0 mM concentrations of AT-101 for 24, 48 and 72 h followed by overnight incubation with ATC or EGFRBi armed ATC (aATC) and measured the cytotoxicity by 51 Cr release assay. Both ATC and EGFRBi armed ATC showed significantly enhanced cytotoxicity in AT-101 primed PC cell lines in a priming time and dose dependent manner. Cytotoxicity by ATC or EFGRBi armed ATC increased significantly (40-70%) after priming of L3.6pl, MiaPaCa-2 and CoLo-357 cells for 72 h with AT-101 at 0.5 mM and 1 mM concentrations, suggesting an additive cytotoxic effect of combination therapy ( Figure 1 ). There was no difference in the cytotoxicity observed in 0.1 mM AT-101 treated or untreated cells, while the 5.0 mM concentration was technically limiting due to the fragility of the primed tumor cells to withstand 51 Cr labeling and multiple washing steps. Since AT-101 did not induce cytotoxicity in the first 24 h at 1 mM concentration, we chose 1 mM AT-101 treatment for 24 h followed by ATC or aATC incubation for 1-4 h in all our subsequent experiments. Considerable apoptosis was observed in L3.6pl cells treated with ATC or aATC after 4 h treatment ( Figure 2 ). 
AT-101 Enhanced Cytotoxic Activity of ATC and aATC
Earlier we have shown that the perforin/granzyme pathway plays a prominent role in ATC and aATC-mediated cytotoxic effects [30] . We therefore examined the effect of 1 mM AT-101 in a 4 h assay on degranulation (CD107a and b) and GrzB release in ATC or aATC when stimulated with target cells. No difference in the proportion of CD107a + and CD107b + cells was observed during incubation of ATC or aATC with 1 mM AT-101 treated or untreated L3.6pl and MiaPaCa-2 for 4 h at 10:1 E/T ratio. However, the number of GrzB + cells increased in both ATC and aATC (p,0.05) when incubated with AT-101 treated tumor cells for 4 h (Figures 3 and 4) . Mean fluorescence intensity (MFI) for CD107a/b and GrzB also increased in both ATC and aATC (p,0.04) in the presence of AT-101 treated L3.6pl cells (Figures 3  and 4) , suggesting that chemotherapy sensitizes tumor cells for enhanced aATC-mediated cytotoxicity via up-regulation of these molecules.
Enhanced IFN-c Expression in aATC During Interaction with AT-101 Treated Tumor Cells
Our previous studies have shown that high levels of IFN-c are produced during aATC-mediated killing of target cells [31, 32] . We examined whether IFN-c participates in AT-101 sensitized tumor cell killing by ATC and aATC, by staining for intracellular IFN-c in ATC and aATC, and by measuring IFN-c in culture supernatant after 4 h co-culture with L3.6pl and MiaPaCa-2 cells either presensitized with AT-101 or left untreated. Intracellular staining for IFN-c showed marked increase in aATC co-cultured with L3.6pl or MiaPaCa-2 cells compared to those treated with ATC (3-7 fold increase in MFI) regardless of AT-101 sensitization. Incubation of aATC with AT-101 treated cells showed significantly higher The signal transducers and activators of transcription (Stat) factors function as downstream effectors of cytokine and growth factor receptor signaling [33, 34] . Constitutive Stat3 activation can lead to resistance to apoptosis [35] . We show that high levels of IFN-c are produced during aATC-mediated targeted killing of tumor cells, thus we reasoned that IFN- (Figure 11 and 12) . Interestingly, ratios of both pBad :Bcl-X L and Bax:Bcl-X L MFI were also noticeably higher (more death) in both cell lines, L3.6pl (pBad :Bcl-X L , p,0.0001; Bax:Bcl-X L , p,0.0001) and MiaPaCa-2 (pBad :Bcl-X L , p,0.005; Bax:Bcl-X L , p,0.05) treated with EGFRBi armed ATC after 24 h AT-101 sensitization ( Figure 13 ).
Discussion
PC is among the deadliest of all malignancies and urgently requires new therapeutic approaches. Pretreatment of tumor cells with small molecule inhibitors or chemotherapeutic drugs has been shown to sensitize tumor cells for enhanced CTL responses by altering the expression levels of key apoptosis regulators [36] [37] [38] . Using this principle, we have for the first time investigated the effect of combination therapy where PC cells were pretreated with suboptimal concentrations of AT-101 followed by incubation with ATC and aATC-mediated cytotoxicity of tumor targets. We observed that 1) sensitization of tumor cells with AT-101 enhanced ATC and aATC-mediated cytotoxicity in L3.6pl, MiaPaCa-2 and CoLo-357 cells; 2) enhanced GrzB uptake of tumor cells; 3) enhanced IFN-c induced Stat1 phosphorylation and Stat3 dephosphorylation, which in turn inhibited Bcl-X L and induced expression of pBad and Bax (Figure 14) . EGFRBi armed ATCmediated apoptosis in AT-101 sensitized L3.6pl and MiaPaCa-2 cells may be facilitated by increased expression of pBad and Bax and partially through repressing Bcl-X L expression.
ATC are known to induce cytotoxicity via Fas/FasL or perforin/granzyme pathways; however, in previous studies we have shown that perforin/granzyme is the predominant pathway of aATC-mediated killing [39] . During effector-target interaction, the pore forming protein perforin is released by activated T cell (ATC) and facilitates the delivery of serine proteases GrzA and GrzB to the target cell cytoplasm and nucleus, where they deliver the apoptotic hits through independent pathways [40] [41] [42] . First, we asked whether interaction of AT-101 sensitized PC cells with ATC or aATC can enhance perforin/granzymes-mediated cytotoxicity of tumor cells by ATC or aATC. Induction of early apoptosis was determined by Annexin V/7-AAD, which showed no difference between untreated tumor cells and tumor cells treated with 1 mM AT-101 (24 h). These data suggest that a suboptimal concentration of AT-101 could not induce apoptosis within 24 h exposure but was sufficient to cause rapid induction of apoptosis following 4 h incubation with ATC or aATC.
We examined the changes in degranulation markers CD107a/b and cytolytic granule GrzB following a 4 h incubation of ATC or aATC with AT-101 treated tumor cells at 10:1 E/T. ATC and Since Stat1 and Stat3 show opposing patterns that promote or inhibit apoptosis, respectively, we examined the expression of antiapoptotic Bcl-X L and pro-apoptotic pBad and Bax proteins in AT-101 sensitized tumor cells in the presence of ATC or aATC. Studies have shown that IFN-c-induced dephosphorylation of Stat3 could induce apoptosis [33] through down-regulation of Bcl-2, Bcl-X L , and Mcl-1, and up-regulation of Bax [47] . AT-101 treated L3.6pl and MiaPaCa-2 cells showed reduced MFI for Bcl-X L and increased MFI for pS 112 -Bad and Bax compared to untreated L3.6pl and MiaPaCa-2 cells in the presence of ATC or aATC; however, the difference was not statistically significant. Intriguingly, the ratio of pBad:Bcl-X L and Bax:Bcl-X L under the same conditions showed a significant difference between AT-101 treated and untreated L3.6pl and MiaPaCa-2 cells. Constitutively high levels of Bcl-2 or Bcl-X L have been associated with drug resistance and more aggressive phenotype in both liquid and solid tumors [48, 49] . Expression of Bcl-X L in the NCI 60 cell line panel strongly correlated with resistance to most chemotherapy agents [50] . Cellular fate between apoptosis and survival depends upon the balance between proapoptotic and antiapoptotic protein levels. High levels of Bcl-X L and low levels of Bax provide a survival advantage and vice versa. Del Poeta et al. (2003) showed that the ratio of Bax/Bcl-2 MFI predicted the outcome in acute myeloid leukemia (AML) [51] . Lower Bax/Bcl-2 levels were correlated with poor-risk cytogenetics; and a longer overall survival (OS) and disease-free survival (DFS) observed in patients with higher Bax/ Bcl-2 levels. Another study in B-CLL showed that enhanced Bcl-2/Bax ratio contributes to B-CLL survival [52] . These results are consistent with our current findings.
While combination of targeted therapies with chemotherapeutic drugs has been tested against PC, this is the first study, to the best of our knowledge, to report that priming of tumor cells with highly specific Bcl-2 inhibitor enhances cytotoxic activity armed ATC. In summary, we have shown that the combination of Bcl-2 inhibitor AT-101 (conditioning of PC cells) with targeted immunotherapy using EGFRBi armed ATC offers an attractive therapeutic approach that can lead to reduced toxicity but potent anti-tumor activity. Priming of tumor cells with suboptimal concentration for short duration can significantly enhance anti-tumor activity of EGFRBi armed ATC through the inhibition of Stat3 and activation of Stat1. These proof-of-concept studies provide rationale to design future strategies for the treatment of pancreatic cancer and warrant further clinical investigations against deadly PC. 
